Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.62 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | CA9 | Q16790 | 7/20 | 0.62 |
| ▸ | CA4 | P22748 | 5/20 | 0.62 |
| ▸ | CA7 | P43166 | 5/20 | 0.62 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
| ▸ | HPN | P05981 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.61 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243497 | 1.00 | KMT2A (0.62) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616407 | 0.84 | KMT2A (0.69) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616387 | 0.84 | KMT2A (0.69) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616413 | 0.84 | KMT2A (0.69) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616435 | 0.83 | KMT2A (0.88) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616428 | 0.83 | KMT2A (0.88) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL31616436 | 0.83 | KMT2A (0.88) | KMT2ADRD2DRD4DRD3DCUN1D1 | |
| SCHEMBL12084919 | 0.81 | CA12 (0.66) | POLBCA12CA1CA2CA9 | |
| SCHEMBL358309 | 0.81 | CA12 (0.66) | POLBCA12CA1CA2CA9 | |
| SCHEMBL31616451 | 0.81 | DCUN1D1 (0.66) | KMT2ADRD2DRD4DRD3DCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-2211865-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| WO-2009050198-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | KMT2A 4190/4885DRD2 651/4885DRD4 352/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | KMT2A 4190/4885DRD2 651/4885DRD4 352/4885 |
| US-20090181934-A1 | Organic Compounds | LTB4R2, LTA4H, LTB4R | KMT2A 3135/4885DRD2 1427/4885DRD4 1099/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | KMT2A 4190/4885DRD2 651/4885DRD4 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.